基于嵌合抗原受体修饰的T细胞(chimeric antigen receptors-modified T cells,CAR-T细胞)疗法是通过基因修饰使T细胞表达肿瘤特异性嵌合抗原受体的一种新型肿瘤免疫疗法,是当前血液肿瘤治疗领域最具前景的研究方向之一。CAR作为一种分...基于嵌合抗原受体修饰的T细胞(chimeric antigen receptors-modified T cells,CAR-T细胞)疗法是通过基因修饰使T细胞表达肿瘤特异性嵌合抗原受体的一种新型肿瘤免疫疗法,是当前血液肿瘤治疗领域最具前景的研究方向之一。CAR作为一种分子修饰物,其结构主要由细胞外抗原识别结构域(通常是抗体单链可变片段scFv)与细胞内信号传导结构域(T细胞受体的CD3ζ链)相连接而成。展开更多
Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia...Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia are at an increased risk for life-threatening obstetric complications.Therefore,we established this consensus statement on the diagnosis and management of ITP during pregnancy(detailed information is available in the Supplementary File,http://links.lww.com7CM9/A978).展开更多
文摘免疫疗法革新了多种癌症的治疗现状。嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在血液肿瘤包括白血病、淋巴瘤和多发性骨髓瘤等疾病的治疗中取得巨大成功。与传统化疗不同的是,CAR-T疗法有独特的不良反应包括细胞因子释放综合征和中枢神经毒性等。自2021年6月以来我国已经批准两款CD19为靶点的CAR-T细胞产品上市,用于治疗难治复发B细胞淋巴瘤;此外,我国有数百项CAR-T治疗血液肿瘤和实体瘤的临床试验正在开展。随着CAR-T疗法在肿瘤治疗中的应用和相关临床研究日益广泛,其不良反应管理的必要性和重要性日益凸显。美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)于2021年11月推出了首部《嵌合抗原受体T细胞疗法的免疫相关不良事件管理:ASCO指南》。本文将结合临床实践对ASCO指南进行解读,以期为CAR-T疗法不良反应的管理带来更深入的理解。
文摘基于嵌合抗原受体修饰的T细胞(chimeric antigen receptors-modified T cells,CAR-T细胞)疗法是通过基因修饰使T细胞表达肿瘤特异性嵌合抗原受体的一种新型肿瘤免疫疗法,是当前血液肿瘤治疗领域最具前景的研究方向之一。CAR作为一种分子修饰物,其结构主要由细胞外抗原识别结构域(通常是抗体单链可变片段scFv)与细胞内信号传导结构域(T细胞受体的CD3ζ链)相连接而成。
基金National Key Research and Development Program of China(No. 2017YFA0105503)National Natural Science Foundation of China(No. 81970113)+1 种基金Key Program of National Natural Science Foundation of China(No. 81730004)Beijing Natural Science Foundation(No. H2018206423)。
文摘Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia are at an increased risk for life-threatening obstetric complications.Therefore,we established this consensus statement on the diagnosis and management of ITP during pregnancy(detailed information is available in the Supplementary File,http://links.lww.com7CM9/A978).
